ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Predicting Outcomes of Indeterminate Bone Lesions on
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Comparative analysis of PSMA-RADS Version 2.0 versus bone uptake metastatic probability (BUMP) score for characterising focal bone uptake on [18F]PSMA-1007 PET/CT in prostate cancer - a multicentre evaluation.European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.European radiology · 2026Article
- Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria.European journal of nuclear medicine and molecular imaging · 2026Article
- Context-level machine learning to improve the identification of lymph node and bone metastases in prostate cancer patients using [EJNMMI physics · 2025Article
- Review
- PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.European radiology · 2025Article
- The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients.Clinical imaging · 2025Article
- Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.Skeletal radiology · 2025Article
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Standardized template for clinical reporting of PSMA PET/CT scans.European journal of nuclear medicine and molecular imaging · 2024Article
- PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.EJNMMI reports · 2024Article
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) PET/CT are common. This study aimed to define variables that predict whether such lesions are likely malignant or benign using features on PSMA PET/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.